North America Blood Plasma Derivatives Market Size, Share & Industry Trends Analysis Report by Application, End-user, Type (Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin), Country and Growth Forecast, 2022-2028

The North America Blood Plasma Derivatives Market should witness market growth of 8.9% CAGR during the forecast period (2022-2028).

Plasma is a transparent, straw-colored liquid component of blood that is composed of a protein salt solution. There are three kinds of blood cells floating in plasma, including white blood cells, red blood cells, and platelets. More than 100 distinct proteins, including albumin, immunoglobulin, fibrinogen, protease inhibitors, and clotting factor, are present in plasma.

It is essential for regulating blood pressure and transferring minerals, such as salt and potassium. Plasma is a liquid component of blood that includes platelets and proteins responsible for blood coagulation. Plasma Derivatives are derived from plasma proteins during the fractionation cycle. The Derivatives are then heat- or chemically-treated dissolvable cleaners that kill certain diseases.

Factor IX concentrate, factor VIII concentrate, hostile to inhibitor coagulation complex (AICC), Alpha 1-Proteinase inhibitor concentrate, against thrombin III concentrate, egg whites, insusceptible globulins, and against thrombin III concentrates are the most well-known plasma derivatives. Clinically, blood plasma derivatives are widely used to treat a variety of illnesses, including HIV, hemophilia A, thrombocytosis, hemophilia B, hepatitis C, hepatitis B, etc.

The North American blood plasma derivatives market is estimated to witness a number of growth prospects throughout the coming years. The regional market is anticipated to grow significantly as a result of rising knowledge about the usage as well as availability of plasma derivatives across the region, as well as the high adoption of sophisticated technology, and the presence of significant manufacturing companies and key market players. Therefore, all of these factors would play a major role in bolstering the growth of the regional blood plasma derivatives market.

The US market dominated the North America Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $19,716.5 Million by 2028. The Canada market is experiencing a CAGR of 11.4% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 10.4% during (2022-2028).

Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.

Scope of the Study

By Application

• Immunodeficiency Diseases
• Hypogammaglobulinemia
• Hemophilia
• Von Willebrand's Disease
• Others

By End-user

• Hospitals
• Clinics
• Others

By Type

• Immunoglobulin
• Albumin
• Factor VIII
• Factor IX
• Hyperimmune Globulin
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Bayer AG
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Biotest AG
• LFB S.A.
• CSL Limited
• Octapharma AG
• Kedrion S.p.A
• Sanofi S.A.
• Fusion Health Care Pvt. Ltd.

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free